Goldman Sachs Reinitiates Coverage on ArriVent Biopharma (AVBP) with Buy Rating | AVBP Stock News

Author's Avatar
Jul 10, 2025

Goldman Sachs has resumed its coverage of ArriVent Biopharma (AVBP, Financial), assigning a Buy rating and setting a price target of $33. The firm anticipates that the results from the Phase 3 FURVENT study will showcase significant clinical effectiveness, thereby strengthening the company's competitive position. This outlook reflects confidence in ArriVent Biopharma's potential to deliver strong performance in the market.

Wall Street Analysts Forecast

1943240008962043904.png

Based on the one-year price targets offered by 8 analysts, the average target price for ArriVent BioPharma Inc (AVBP, Financial) is $41.13 with a high estimate of $45.00 and a low estimate of $37.00. The average target implies an upside of 92.71% from the current price of $21.34. More detailed estimate data can be found on the ArriVent BioPharma Inc (AVBP) Forecast page.

Based on the consensus recommendation from 8 brokerage firms, ArriVent BioPharma Inc's (AVBP, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.